Juvaris Signs Strategic Collaboration With ADi

Juvaris has signed an agreement with Antigen Discovery (ADi) to access ADi’s high-throughput protein microarray screening system to discover novel disease-specific antigens.

Juvaris will sponsor research for multiple disease targets and pay ADi upfront payments, development milestones and royalties on licensed products, in exchange for full product development rights to all fields except diagnostics, which will belong to ADi.

Juvaris will select the optimal antigens from the ADi discovery efforts to combine with its proprietary adjuvant technology, to create highly immunogenic prophylactic and therapeutic vaccines against major unmet medical needs.

Keith Hoffman, Head of Business Development at ADi, said: “This broad collaboration with Juvaris allows us to leverage our validated antigen discovery engine for vaccine development. After screening thousands of patient samples, we have proven the utility of our platform across multiple infectious diseases. We very much look forward to working with Juvaris to discover important antigens to facilitate not only vaccine development to prevent or treat disease, but also diagnostics to manage disease.”